Structure-based design has gained credibility as a valuable component of the modern drug discovery process. The technique of SSNMR (solid-state NMR) promises to be a useful counterpart to the conventional experimental techniques of X-ray crystallography and solution-state NMR for providing structural features of drug targets that can guide medicinal chemistry towards drug candidates. This article highlights some recent SSNMR approaches from our group for identifying active compounds, such as enzyme inhibitors, receptor antagonists and peptide agents, that prevent the aggregation of amyloid proteins involved in neurodegenerative diseases. It is anticipated that the use of SSNMR in drug discovery will become more widespread in the wake of advances in hardware and methodological developments.
Introduction
There are now numerous examples of how the search for new drug candidates has been hastened by structural information provided by X-ray crystallography, NMR spectroscopy and predictive in silico methods [1] [2] [3] [4] . A general approach to rational structure-based drug design begins with the structure of a target protein that has been determined experimentally or by homology modelling. Computational methods are then used to position compounds or fragments available from a library into selected regions of the structure. The compounds predicted to have the most favourable interactions with the target site are then screened for activity. Often a second cycle of structure determination of the target in complex with the best leads from the first iteration can suggest how the compounds can be optimized to produce sub-micromolar ligands, for example by linking together smaller fragments [5] .
A sizeable proportion of drug targets are not readily amenable to structural analysis by conventional techniques owing to the insolubility of the target in aqueous environments. A prime example is found in the proteins that function from within cellular membranes, most notably the GPCRs (G-protein-coupled receptors), which constitute over half of the targets for currently marketed drugs [6] . The structural database of membrane proteins is growing at a steady pace, but handling difficulties have hampered crystallographic studies and, until recently, have precluded structural analysis of membrane proteins by solution NMR. Alongside membrane-embedded proteins, amyloid fibrils represent another important class of disease targets that may be classified as being insoluble in their disease-associated forms. These protein aggregates are deposited as pathological lesions within areas of the brain and other tissues [7] and are associated with devastating and widespread diseases including Alzheimer's, Parkinson's and Type 2 diabetes. An attractive therapeutic strategy is to develop drugs that inhibit the aggregation process and arrest or impede the formation of the toxic amyloid species [8] . The search for such therapies would again benefit from knowledge of the structural details of the amyloid target.
SSNMR (solid-state NMR) is proving to be a powerful tool for the structural analysis of membrane proteins and amyloid fibrils [9] and is attracting attention as a potentially valuable counterpart to the conventional methods for structure-based drug design. SSNMR embraces a collection of diverse methods that take advantage of the spatial and dynamic properties of solid and semi-solid materials such as biomembranes and protein assemblies to extract information about structure and dynamics [10, 11] . Some examples are discussed here, from this research group, of how SSNMR can contribute to the early phases of drug design and discovery.
Mapping the ligand-binding sites of membrane-embedded receptors
A convenient starting point in structure-based drug discovery is to identify where the native ligand or an unoptimized lead compound interacts with its target and to produce a three-dimensional model of the ligand within the binding pocket. The SSNMR method of CP-MAS (cross-polarization magic-angle spinning) can be used to obtain high-resolution spectra from which to detect weak interactions of ligands with receptors embedded in native membrane or isolated and incorporated into defined lipid bilayers [12] [13] [14] . When an isotopically labelled (e.g. 13 C, 15 N or 19 F) ligand is added to a membrane sample, a peak from the ligand is observed in the NMR spectrum only if the mobility of the ligand is restrained by the membrane protein target [12] . The advantage of CP-MAS is that, with appropriate control experiments, specific ligand binding can be observed even when the target receptor constitutes less than 20% of the total protein present in the membrane sample which alleviates the requirement for purification procedures. CP-MAS can also provide quantitative information about ligand-binding affinities by monitoring the build-up of peak intensities at different ligand concentrations, NMR contact times or in the presence of competitor ligands. Plots of NMR peak intensities for a ligand can be compared with simulated curves to extract dissociation constants. By measuring ligand-binding constants for mutants of the target receptor, CP-MAS can also be used to map the binding sites of ligands in membrane-embedded receptors. This approach has been applied to the bacterial nucleoside transport protein NupC for which a number of mutants (including G146C) have cross-polarization buildup curves that are consistent with reduced substrate-binding affinity in comparison with the wild-type protein ( Figure 1 ). These results suggest that the the substituted residues are situated close to the substrate-binding site.
A powerful feature of SSNMR is its ability to detect direct interactions between specific residues in a target protein and the bound ligand. Smith and co-workers used two-dimensional SSNMR experiments to identify couplings between 13 C-labelled tyrosine, glycine, serine and threonine residues around the binding pocket of the GPCR rhodopsin and the covalently linked chromophore retinal [15] . It was shown that the transition of rhodopsin to the M II state involves the disruption of helix-helix interactions in the transmembrane domain as retinal moves some 5 Å (1 Å = 0.1 nm) towards helix 5 and the C-20 methyl group of retinal moves towards extracellular loop 2. We have recently applied similar methods to identify interactions between 13 C-labelled tryptophan residues in the sugar transport protein GalP from Escherichia coli and the bound substrate glucose. In this case it was necessary to modify the methodology to overcome difficulties associated with weak non-covalent receptor-ligand interactions, which now extends the range of this approach into the realm of important drug targets such as GPCRs.
Structures of bound ligands
SSNMR can provide information about the molecular conformations of native ligands, lead compounds and drugs bound to target receptors. Such information can be exploited to refine the structures of known ligands to improve binding affinity or efficacy. This approach was first shown for flexible inhibitors of the gastric H + /K + -ATPase, a proton pump that is responsible for secretion of acid into gastric glands and is thus a target for drugs in the treatment of gastric ulcer disease. SSNMR measurements of conformationally diagnostic 13 C-13 C and 13 C- 19 F distances between labels placed within a bound inhibitor revealed details about how it interacts with its target even in the absence of a high-resolution structure for this protein. The SSNMR measurements suggested how the inhibitor could be chemically constrained in its active conformation to produce an analogue that is 10 times more active than the flexible inhibitor [16, 17] . Similar experiments have also given insights into how a homologous protein, the cardiac Na + /K + -ATPase, is inhibited by high-affinity cardiac glycoside inhibitors, collectively known as digitalis, which have been used for over 200 years in the treatment of congestive heart failure [18] .
These methods are ideally suited to determining the structures of GPCR ligands in their active sites, which remains a major goal for this group and for others in academia and industry. Progress has been slow, however, owing to technical difficulties in the synthesis of suitably isotope-labelled ligands to provide sufficient geometric constraints on molecular conformation, compounded by the lack of availability of GPCRs in high enough quantities for NMR analysis. We are taking measures in this laboratory to alleviate the first problem, and the second issue is being overcome by collaborations with scientists in the pharmaceutical industry who have the resources and expertise to express and purify receptors on a large scale. Our developments in these areas are described below.
Most SSNMR experiments on membrane proteins, and their bound ligands, substrates and prosthetic groups, rely on direct observation of couplings between naturally rare nuclei ( 13 C, 15 N, 2 H and 19 F) in isotope-enriched samples rather than direct measurements of proton-proton couplings, which present certain technical difficulties. Unfortunately the number of sites in a ligand that can be isotopically labelled is generally rather low owing to the limited availability of labelled precursors and by restrictions in the synthetic route [19] . Consequently, for a typical ligand having three or more degrees of conformational freedom, the number of geometric constraints (interatomic distances and angles) is insufficient to determine the ligand conformation unambiguously. A good example of this is the histamine H 2 GPCR antagonist cimetidine. Cimetidine can be prepared by the commercial synthetic route with a 13 C label and a 15 N label at the two ends of the molecule (Figure 2a ) but the introduction of additional labels would require a significant investment of resource and expense. The 13 C-13 C distance in the solid crystalline form is approx. 3.7 Å , but a conformation grid search varying each of the seven degrees of freedom in 30
• increments identifies over 5000 'hits' consistent with this constraint. We have therefore devised a strategy in which the bonded protons are utilized indirectly to provide three additional constraints from the same double-labelled compound [20] . By measuring C-N-H, H-C-N and H-C-N-H angles, the number of hits can be reduced to less than 20, all of which fall within just two closely related families of conformations (Figure 2a) . The H 2 receptor is not yet available to us in sufficient quantitites to repeat these experiments for cimetidine bound to its target, but this strategy is instead being applied to determine the conformation of β 2 -adrenergic receptor ligands salbutamol and salmeterol in their binding site. In collaboration with pharmaceutical companies, the β 2 -adrenergic receptor has been prepared retaining ligand binding in its native membrane and reconstituted into lipid bilayers suitable for NMR analysis.
Structure-based design of amyloid inhibitors
All amyloid fibrils contain repeat arrays of β-strands arranged with interstrand hydrogen bonds parallel to the fibril long axis. The three-dimensional architecture of amyloid fibrils varies from protein to protein, but involves a complex network of electrostatic, van der Waals and π -π interactions between amino acid side groups, which bring together laminae of β-sheets arranged with water-exposed faces and waterexcluded cores. SSNMR is the method of choice for probing polypeptide structures and intermolecular contacts in intact amyloid fibrils and could therefore be useful in drug design.
An attractive therapeutic strategy for preventing amyloid deposition in brain and other tissues is to identify agents that interfere with the fibril growth process by arresting the onset or propagation of fibril growth [8, 21, 22] . Information about the structural features of an amyloid species could help to identify inhibitors of amyloidogenic proteins. SSNMR can assist in this process by identifying specific interactions between amino acid side groups that could be targeted by agents aimed at destabilizing the growing fibrils or preventing the lateral association of β-sheet layers. For example, SSNMR measurements of interactions between 2 H-and 19 F-labelled phenylalanine side groups in fibrils formed by a fragment of the hIAPP (human islet amyloid polypeptide) reveals that aromatic π -π interactions might contribute to the overall architecture that holds the fibrils together [23] (Figure 3a) .
One approach that is gathering interest is to synthesize short peptides that correspond to a SRE (self-recognition element) of the native amyloid sequence, but containing key modifications so that the peptides bind to the complementary sequence of the aggregating parent protein and prevent further aggregation. A convenient and useful way to modify an SRE peptide is to introduce N-methylated Figure 2 Experiments toward the conformational analysis of isotopically labelled ligands when bound to GPCRs (a) The histamine H 2 receptor antagonist cimetidine can be labelled with 15 N and 13 C at the sites denoted by asterisks (top). A SSNMR strategy to measure multiple distance and angle constraints for [ 13 C, 15 C]cimetidine in the crystalline state obtained by SSNMR (centre) restricts the conformation of the molecule to two similar families (bottom), which are close to the true conformation determined by X-ray crystallography. This approach is now being adapted for the structural analysis of salbutamol and salmeterol bound to the β 2 -adrenergic receptor β 2 AR (b). Salbutamol (top) is amenable to extensive isotope labelling via existing synthetic routes. The β 2 -adrenergic receptor has been cloned and expressed with an N-terminal His 6 tag, an N-terminal FLAG tag and mutated at two glycosylation sites using the Bac-to-Bac R baculovirus expression system (Invitrogen). An SDS/PAGE gel of the purified receptor after both FLAG-and His-affinity chromatography steps shows bands from the receptor which were identified using MS analysis and immunoblotting using a horseradish-peroxidase-conjugated anti-FLAG M2 antibody (middle). The detergent-solubilized receptor retains the ability to bind salmeterol (bottom). BAP, bacterial alkaline phosphatase.
backbone amide groups so that the peptide is unable to hydrogen-bond on one side [24] [25] [26] [27] . SSNMR can guide the design of modified SRE peptides by first identifying which amino residues of the unmodified peptides are essential for aggregation and which are redundant. This is done by constructing an amyloidogenicity profile for the peptide based on chemical shifts and NMR peak widths. The flanking sequences of residues that are redundant in the aggregation of the peptide can then be eliminated leaving only the core residues, usually six to eight in number. One or more of these remaining residues can then be modified (e.g. by N-methylation) and screened for their effects on aggregation (a) Analysis of fibrils formed by a fragment of IAPP (islet amyloid polypeptide) reveals interactions between aromatic side groups of adjacent β-sheets, which could be targeted by compounds to prevent fibril assembly or destabilize pre-existing protofilaments. (b) A strategy for designing peptide inhibitors of amyloid formation. Fibrils of peptide fragments corresponding to SREs of the parent protein are analysed by SSNMR to provide an amyloidogenicity profile which pinpoints which amino acid residues are necessary for fibril formation and which are redundant. The peptide fragment is truncated to leave five or six essential core amino acids, which are modified (e.g. with N-methyl groups) and tested for inhibition. In successful cases, the modified peptides bind to the complementary sequence of the aggregating parent protein and prevent further elongation of the fibrils.
of the parent amyloid protein (Figure 3b ). This approach has recently been used successfully to design an N-methylated peptide which prevents the aggregation of α-synuclein, the main protein component of Lewy bodies associated with Parkinson's disease and other neurodegenerative disorders.
Outlook
Examples of how SSNMR can assist structure-based design and drug discovery are, at present, few and far between and the technique is underexploited as a tool for drug design. With advances in instrumentation and magnet technology, sample preparation and methodology, the future of SSNMR in drug discovery looks positive. Entire structures of proteins in the solid state, including membrane proteins and amyloid fibrils, are now being solved by NMR, and this technique promises to offer a realistic alternative to X-ray crystallography in providing the structures of experimentally challenging drug targets as the starting point for drug design.
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